As of Jul 16
| -0.03 / -3.53%|
The 3 analysts offering 12-month price forecasts for Catabasis Pharmaceuticals Inc have a median target of 6.00, with a high estimate of 7.00 and a low estimate of 2.50. The median estimate represents a +631.71% increase from the last price of 0.82.
The current consensus among 3 polled investment analysts is to Buy stock in Catabasis Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.